Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Selenbio Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. This indicates a concentrated prosecution profile with no current diversity in examiners or art units. Practitioners should recognize that this case represents the company's current engagement with the patent office in this technology area. The focus on a single examiner and unit suggests a streamlined interaction with the office.
ROCHELLE, CIERRA MARIE is the busiest examiner, managing the busiest examiner pending count of 1. With only 1 distinct examiner and 1 distinct art unit involved, the company's immediate patent goals are focused on this single action. Practitioners should tailor their strategy to the specific requirements of the 1 distinct art unit, as it is the only one currently reviewing the company's pending office actions. The outcome of the 1 pending office action will define the company's current success rate within the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROCHELLE, CIERRA MARIE | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18870903 | ORGANIC DISELENIDE COMPOSITION | ROCHELLE, CIERRA MARIE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18870903 | ORGANIC DISELENIDE COMPOSITION | ROCHELLE, CIERRA MARIE | 1627 | §112 | Non-Final OA | — | Pending | Dec 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSelenbio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Cierra Marie Rochelle has the most, with 1 of Selenbio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
